Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

Cited In for PubMed (Select 17936556)

1.

TP53: an oncogene in disguise.

Soussi T, Wiman KG.

Cell Death Differ. 2015 Aug;22(8):1239-49. doi: 10.1038/cdd.2015.53. Epub 2015 May 29. Review.

PMID:
26024390
2.

TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma.

Rebbani K, Marchio A, Ezzikouri S, Afifi R, Kandil M, Bahri O, Triki H, El Feydi AE, Dejean A, Benjelloun S, Pineau P.

Mol Cancer. 2015 Apr 2;14:74. doi: 10.1186/s12943-015-0340-2.

3.

Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer.

Chen P, Hu T, Liang Y, Jiang Y, Pan Y, Li C, Zhang P, Wei D, Li P, Jeong LS, Chu Y, Qi H, Yang M, Hoffman RM, Dong Z, Jia L.

Oncotarget. 2015 Apr 20;6(11):9002-17.

4.

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.

McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF.

Blood Cancer J. 2015 Mar 13;5:e291. doi: 10.1038/bcj.2015.11.

5.

Exercise Increases Markers of Spermatogenesis in Rats Selectively Bred for Low Running Capacity.

Torma F, Koltai E, Nagy E, Ziaaldini MM, Posa A, Koch LG, Britton SL, Boldogh I, Radak Z.

PLoS One. 2014 Dec 10;9(12):e114075. doi: 10.1371/journal.pone.0114075. eCollection 2014.

6.

Sphingolipids in the DNA damage response.

Carroll B, Donaldson JC, Obeid L.

Adv Biol Regul. 2015 May;58:38-52. doi: 10.1016/j.jbior.2014.11.001. Epub 2014 Nov 18.

PMID:
25434743
7.

Anti-apoptotic NF-κB and "gain of function" mutp53 in concert act pro-apoptotic in response to UVB+IL-1 via enhanced TNF production.

Müller I, Beissert S, Kulms D.

J Invest Dermatol. 2015 Mar;135(3):851-60. doi: 10.1038/jid.2014.481. Epub 2014 Nov 7.

8.

TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients.

Fernandez SV, Bingham C, Fittipaldi P, Austin L, Palazzo J, Palmer G, Alpaugh K, Cristofanilli M.

Breast Cancer Res. 2014 Oct 9;16(5):445. doi: 10.1186/s13058-014-0445-3.

9.

Involvement of p53 mutation and mismatch repair proteins dysregulation in NNK-induced malignant transformation of human bronchial epithelial cells.

Shen Y, Zhang S, Huang X, Chen K, Shen J, Wang Z.

Biomed Res Int. 2014;2014:920275. doi: 10.1155/2014/920275. Epub 2014 Aug 18.

10.

A step closer toward therapies for p63-related disorders.

Zhou H, Aberdam D.

Rare Dis. 2013 Mar 12;1:e24247. doi: 10.4161/rdis.24247. eCollection 2013.

11.

IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients.

Stancheva G, Goranova T, Laleva M, Kamenova M, Mitkova A, Velinov N, Poptodorov G, Mitev V, Kaneva R, Gabrovsky N.

Biomed Res Int. 2014;2014:654727. doi: 10.1155/2014/654727. Epub 2014 Apr 24.

12.

Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response.

Nair BC, Krishnan SR, Sareddy GR, Mann M, Xu B, Natarajan M, Hasty P, Brann D, Tekmal RR, Vadlamudi RK.

Cell Death Differ. 2014 Sep;21(9):1409-18. doi: 10.1038/cdd.2014.55. Epub 2014 May 2.

PMID:
24786831
13.

Combined effects of genetic variants of the PTEN, AKT1, MDM2 and p53 genes on the risk of nasopharyngeal carcinoma.

Zhang X, Chen X, Zhai Y, Cui Y, Cao P, Zhang H, Wu Z, Li P, Yu L, Xia X, He F, Zhou G.

PLoS One. 2014 Mar 14;9(3):e92135. doi: 10.1371/journal.pone.0092135. eCollection 2014.

14.

Investigation of genetic polymorphisms related to the outcome of radiotherapy for prostate cancer patients.

Cintra HS, Pinezi JC, Machado GD, de Carvalho GM, Carvalho AT, dos Santos TE, Marciano RD, Soares Rde B.

Dis Markers. 2013;35(6):701-10. doi: 10.1155/2013/762685. Epub 2013 Nov 11.

15.

Novel perspective: exercise training stimulus triggers the expression of the oncoprotein human double minute-2 in human skeletal muscle.

Roudier E, Aiken J, Slopack D, Gouzi F, Mercier J, Haas TL, Gustafsson T, Hayot M, Birot O.

Physiol Rep. 2013 Jul;1(2):e00028. doi: 10.1002/phy2.28. Epub 2013 Jul 15.

16.

Regulatory Roles for Long ncRNA and mRNA.

Karapetyan AR, Buiting C, Kuiper RA, Coolen MW.

Cancers (Basel). 2013 Apr 26;5(2):462-90. doi: 10.3390/cancers5020462.

17.

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.

Peng X, Zhang MQ, Conserva F, Hosny G, Selivanova G, Bykov VJ, Arnér ES, Wiman KG.

Cell Death Dis. 2013 Oct 24;4:e881. doi: 10.1038/cddis.2013.417.

18.

p53 talks to PARP: the increasing complexity of p53-induced cell death.

Wiman KG.

Cell Death Differ. 2013 Nov;20(11):1438-9. doi: 10.1038/cdd.2013.111. No abstract available.

19.

A cell-permeable fusion protein based on Clostridium botulinum C2 toxin for delivery of p53 tumorsuppressor into cancer cells.

Fahrer J, Rausch J, Barth H.

PLoS One. 2013 Sep 5;8(9):e72455. doi: 10.1371/journal.pone.0072455. eCollection 2013.

20.

Critical roles of p53 in epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma cells.

Wang Z, Jiang Y, Guan D, Li J, Yin H, Pan Y, Xie D, Chen Y.

PLoS One. 2013 Sep 2;8(9):e72846. doi: 10.1371/journal.pone.0072846. eCollection 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk